Nutraceutical combination (red yeast rice, berberine and policosanols) improves aortic stiffness in low-moderate risk hypercholesterolemic patients

[1]  Shu Meng,et al.  Berberine ameliorates inflammation in patients with acute coronary syndrome following percutaneous coronary intervention , 2012, Clinical and experimental pharmacology & physiology.

[2]  F. Pelliccia,et al.  Long-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patients , 2011, Advances in therapy.

[3]  Yun-Lian Lin,et al.  Inhibition of endothelial adhesion molecule expression by Monascus purpureus-fermented rice metabolites, monacolin K, ankaflavin, and monascin. , 2011, Journal of the science of food and agriculture.

[4]  Yongjae Lee,et al.  Effects of coenzyme Q10 on arterial stiffness, metabolic parameters, and fatigue in obese subjects: a double-blind randomized controlled study. , 2011, Journal of medicinal food.

[5]  Baracco,et al.  The treatment of hypercholesterolemic children: efficacy and safety of a combination of red yeast rice extract and policosanols. , 2009, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[6]  L. Saccá,et al.  Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study. , 2010, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[7]  S. Shyue,et al.  Anti‐atherogenic effect of berberine on LXRα‐ABCA1‐dependent cholesterol efflux in macrophages , 2010, Journal of cellular biochemistry.

[8]  M. Elisaf,et al.  The effect of statin therapy on arterial stiffness by measuring pulse wave velocity: a systematic review. , 2010, Current vascular pharmacology.

[9]  D. Rader,et al.  Role of dietary supplements in lowering low-density lipoprotein cholesterol: a review. , 2010, Journal of clinical lipidology.

[10]  C. Vlachopoulos,et al.  Prediction of Cardiovascular Events and All-Cause Mortality With Arterial Stiffness , 2011 .

[11]  C. Marinangeli,et al.  Policosanols as Nutraceuticals: Fact or Fiction , 2010, Critical reviews in food science and nutrition.

[12]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[13]  G Thippeswamy,et al.  Octacosanol isolated from Tinospora cordifolia downregulates VEGF gene expression by inhibiting nuclear translocation of NF-B and its DNA binding activity. , 2008, European journal of pharmacology.

[14]  D. Capuzzi,et al.  Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. , 2008, The American journal of cardiology.

[15]  Z. Yang,et al.  Berberine-induced mobilization of circulating endothelial progenitor cells improves human small artery elasticity , 2008, Journal of Human Hypertension.

[16]  L. Rovati,et al.  Eulipidemic Effects of Berberine Administered Alone or in Combination with Other Natural Cholesterol-lowering Agents , 2007, Arzneimittelforschung.

[17]  R. Más,et al.  Protective effect of policosanol on endothelium and intimal thickness induced by forceps in rabbits. , 2007, Journal of medicinal food.

[18]  R. Paltriccia,et al.  Effects of rosuvastatin on 3-nitrotyrosine and aortic stiffness in hypercholesterolemia. , 2007, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[19]  B. Janetzky,et al.  Enrichment of coenzyme Q10 in plasma and blood cells: defense against oxidative damage , 2007, International journal of biological sciences.

[20]  Michael F Dulin,et al.  Policosanol is ineffective in the treatment of hypercholesterolemia: a randomized controlled trial. , 2006, The American journal of clinical nutrition.

[21]  Jianpin Liu,et al.  Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials , 2006, Chinese medicine.

[22]  R. Paltriccia,et al.  Increased Ratio of CD31+/CD42− Microparticles to Endothelial Progenitors as a Novel Marker of Atherosclerosis in Hypercholesterolemia , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[23]  Ralf Degenhardt,et al.  Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial. , 2006, JAMA.

[24]  L. Rovati,et al.  Antiatherosclerotic efficacy of policosanol, red yeast rice extract and astaxanthin in the rabbit. , 2011, Arzneimittel-Forschung.

[25]  E. Mannarino,et al.  Attenuation of inflammation with short-term dietary intervention is associated with a reduction of arterial stiffness in subjects with hypercholesterolaemia , 2004, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[26]  Satoru Inaba,et al.  Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins , 2004, Nature Medicine.

[27]  C. Borghi,et al.  Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study. , 2004, American heart journal.

[28]  E. Mannarino,et al.  Low‐grade systemic inflammation impairs arterial stiffness in newly diagnosed hypercholesterolaemia , 2004, European journal of clinical investigation.

[29]  D. Kritchevsky,et al.  Hypolipidemic and anti-atherogenic effects of long-term Cholestin (Monascus purpureus-fermented rice, red yeast rice) in cholesterol fed rabbits. , 2003, The Journal of nutritional biochemistry.

[30]  D. Webb,et al.  Increased central pulse pressure and augmentation index in subjects with hypercholesterolemia. , 2002, Journal of the American College of Cardiology.

[31]  I. Gouni-Berthold,et al.  Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent. , 2002, American heart journal.